Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 3/20 | 0.44 |
| ▸ | EDNRA | P25101 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009624 | 0.91 | EDNRB (0.41) | EDNRBEDNRASRCALDH1A1LMNA | |
| SCHEMBL4434185 | 0.90 | DHPS (0.42) | EDNRBEDNRASRCALDH1A1LMNA | |
| SCHEMBL4427054 | 0.86 | EDNRB (0.43) | EDNRBEDNRASRCALDH1A1LMNA | |
| SCHEMBL8325304 | 0.84 | ALDH1A1 (0.42) | EDNRBEDNRASRCALDH1A1LMNA | |
| SCHEMBL7298739 | 0.83 | CDK1 (0.43) | EDNRBEDNRAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7013160 | 0.81 | EDNRB (0.41) | EDNRBEDNRASRCALDH1A1LMNA | |
| SCHEMBL1748605 | 0.79 | ALDH1A1 (0.56) | ALDH1A1LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL7329617 | 0.79 | ALDH1A1 (0.40) | EDNRBEDNRAALDH1A1HTR2ASLC6A4 | |
| SCHEMBL8323293 | 0.79 | CA12 (0.50) | ALDH1A1LMNASMN1; SMN2HPGDKDM4E | |
| SCHEMBL8328086 | 0.78 | ALDH1A1 (0.40) | EDNRBEDNRAALDH1A1SMN1; SMN2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569914-B1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-18 | — | — | EP | disclosed |
| EP-1569914-B1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2002053557-A1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-07-11 | — | — | WO | disclosed |
| EP-0713875-B1 | Sulfonamides | HOFFMANN LA ROCHE (CH) | 2001-03-21 | — | — | EP | disclosed |
| EP-0526708-B1 | Sulfonamide, preparation and use thereof as medicine and intermediate | HOFFMANN LA ROCHE (CH) | 2000-10-18 | — | — | EP | disclosed |
| EP-0633259-B1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | HOFFMANN LA ROCHE (CH) | 1999-01-13 | — | — | EP | disclosed |
| US-5837708-A | CARDIOVASCULAR DISORDERS OF HYPERTENSION, ISCHEMIA, ANGINA PECTORIS AND VASOSPASMS | HOFFMANN-LA ROCHE INC. (US) | 1998-11-17 | — | — | US | disclosed |
| US-5541186-A | ENDOTHELIN RECEPTOR INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1996016963-A1 | SULFONAMIDES AND THEIR USE AS MEDICAMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0713875-A1 | Sulfonamides | F. Hoffmann-La Roche AG (CH) | 1996-05-29 | — | — | EP | disclosed |
| EP-0633259-A1 | Sulfonylaminopyrimidines, their preparation and their use as medicine | F. HOFFMANN-LA ROCHE AG (CH) | 1995-01-11 | — | — | EP | disclosed |
| EP-0526708-A1 | Sulfonamide, preparation and use thereof as medicine and intermediate | F. HOFFMANN-LA ROCHE AG (CH) | 1993-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | EDNRA, EDNRB, AGTR2 | EDNRB 2/4885EDNRA 1/4885SRC 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.